bioAffinity Secures Japanese Patent Allowance for CyPath Lung, Strengthening International IP

What happened

bioAffinity Technologies announced on October 8, 2026 that it received a notice of allowance from the Japanese Patent Office for a patent covering its noninvasive CyPath Lung diagnostic test and the accompanying AI-built algorithm. This development extends the company's intellectual property protection into Japan, potentially supporting future commercialization efforts in the Asian market. The news comes while the company continues to face significant near-term financial challenges, including high cash burn and going-concern warnings highlighted in recent filings. The master report assigned a WAIT rating, citing strong CyPath Lung adoption but inadequate consolidated revenue growth and dilutive financing risk. While the patent allowance reinforces the long-term technology moat, it does not address the immediate liquidity and revenue mix issues that weigh on the investment thesis.

Implication

Investors should view this patent allowance as a minor positive that strengthens bioAffinity's intellectual property portfolio and future international options. However, the patent does not generate immediate revenue or reduce the company's cash burn, which remains a critical concern. The master report's WAIT rating remains appropriate, as the fundamental issues of dilution risk and slow consolidated revenue recovery persist. The news may provide a short-term sentiment boost, but sustainable stock appreciation will require proof of improved financial performance in upcoming quarters. Investors should monitor Q2 and Q3 results for evidence of CyPath Lung revenue exceeding $500,000 quarterly and a reduction in operating losses before considering re-rating.

Thesis delta

The thesis remains unchanged: BIAF is a WAIT due to persistent cash burn and dilution risk despite strong CyPath Lung adoption. The Japanese patent allowance strengthens the company's long-term IP position but does not address the near-term liquidity challenges or revenue mix issues. Consequently, the fundamental call stays the same, with no upgrade or downgrade warranted by this news alone.